Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 chimeric anti-CD37 antibody radionuclide conjugate - Nordic Nanovector

Next Previous
X
Search
Drug Profile

Lutetium-177 chimeric anti-CD37 antibody radionuclide conjugate - Nordic Nanovector

Alternative Names: 177Lu-DOTA-NNV003; 177Lu-NNV003; CD37-targeting radioimmunoconjugate Humalutin®; Chimeric anti-CD37 ARC; Humalutin®

Latest Information Update: 14 Sep 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nordic Nanovector
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Non-Hodgkin's lymphoma

Most Recent Events

  • 03 May 2022 Pharmacodynamics data from a preclinical study in Non-Hodgkin's lymphoma released by Nordic Nanovector
  • 01 Jan 2016 Preclinical trials in Non-Hodgkin's lymphoma in Norway (IV), prior to January 2016

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top